Publicaciones científicas
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel A (1), Cervantes A (2), Chau I (3), Daniele B (4), Llovet JM (5), Meyer T (6), Nault JC (7), Neumann U (8), Ricke J (9), Sangro B (10), Schirmacher P (11), Verslype C (12), Zech CJ (13), Arnold D (14), Martinelli E (15); ESMO Guidelines Committee.
The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last 20 years and is expected to increase until 2030 in some countries including the United States, while in other countries, such as Japan, the incidence has started to decline [1., 2., 3.].
In 2012, liver cancer represented the fifth most common cancer in men (554 000 new cases) and the ninth in women (228 000 new cases) and the second most common cause of cancer-related death (746 000 estimated deaths), worldwide [3].
The incidence varies from 3/100 000 in Western countries, to 78.1/100 000 in Mongolia, with the highest incidence in Africa and Asia, mapping the geographical distribution of viral hepatitis B (HBV) and hepatitis C (HCV), the most important causes of chronic liver disease and HCC [4].
In Europe, in 2012 the estimated incidence rate was 10.0 in men and 3.3 in women per 100 000, respectively, while the estimated mortality rate was 9.1 and 3.3 per 100 000 in men and women, respectively [3]. The incidence of HCC shows a strong male preponderance and increases progressively with advancing age in all populations.
The association of chronic liver disease and HCC represents the basis for preventive strategies, including universal vaccination at birth against HBV [I, A] [5] and early antiviral treatment of viral HBC and HCV [III, A] [6., 7., 8.].
CITA DEL ARTÍCULO Ann Oncol. 2018 Oct;29 Suppl 4:iv238-iv255. doi: 10.1093/annonc/mdy308
Nuestros autores
